Please provide your email address to receive an email when new articles are posted on . Click here to read the Cover Story, “After decades with only one option, new therapies emerge for congenial ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Patients with 21-hydroxylase deficiency (21-OHD) had lower final height despite early diagnosis. They also experienced earlier onset and a prolonged duration of puberty. Growth-promoting therapies ...
Glucocorticoid replacement therapy is the current standard of care for congenital adrenal hyperplasia (CAH). However, new therapeutic strategies that can better recapitulate physiological requirements ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
To update the congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency clinical practice guideline published by the Endocrine Society in 2010. The writing committee presents updated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results